- Restless Legs Syndrome (RLS), a neurological disorder characterized by an uncontrollable urge to move the legs, is gaining medical and commercial attention due to its impact on sleep quality and daily functioning, particularly among the elderly and individuals with chronic health conditions such as diabetes and kidney disease
- The rising prevalence of primary and secondary RLS, increased awareness among healthcare providers and patients, and growing accessibility to effective pharmacological treatments such as dopaminergic agents, anti-seizure medications, and opioids are fueling demand for targeted therapies and clinical intervention
- North America dominates the global RLS market with the largest revenue share 41.6% in 2025, attributed to a well-established healthcare infrastructure, high diagnosis rates, greater awareness, and the presence of leading pharmaceutical companies. The United States, in particular, shows strong demand for both branded and generic drug formulations, supported by favorable reimbursement frameworks and clinical guidelines
- Asia-Pacific is projected to be the fastest-growing region in the RLS market during the forecast period due to rising geriatric population, increasing healthcare access, and growing awareness about neurological disorders across emerging economies like India and China
- Pharmacological therapies are expected to remain the dominant therapy type, accounting for a significant market share 76.4% in 2025, due to the availability of effective medications and continued R&D investment in drug development targeting dopamine pathways and central nervous system regulation
